期刊文献+

VDCAG方案联合供者淋巴细胞输注治疗老年人急性单核细胞白血病合并肠道浸润1例并文献复习

VDCAG treatment regimen combined with donor lymphocyte infusion for elderly acute monocytic leukemia patients with intestinal tract infiltration:report of 1 case and review of literature
原文传递
导出
摘要 目的探讨VDCAG(维奈克拉+地西他滨+阿柔比星+阿糖胞苷+重组人粒细胞集落刺激因子)方案联合供者淋巴细胞输注(DLI)治疗老年急性单核细胞白血病合并肠道浸润患者的效果和安全性。方法回顾性分析2020年2月济南市第四人民医院收治的1例老年急性单核细胞白血病合并肠道浸润患者的诊疗过程, 并复习相关文献。结果患者为72岁男性, 因乏力、盗汗、食欲减退进行性加重, 行骨髓穿刺、基因突变筛查等相关检查后, 综合诊断为急性单核细胞白血病伴髓外(肠道)浸润、肺部感染。经1个疗程VDCAG方案联合DLI治疗后,达到完全缓解, 血常规恢复正常, 白血病肠道浸润治愈, 继续给予原方案巩固治疗8个疗程。治疗过程中不良反应轻微。结论 VDCAG方案联合DLI治疗老年人急性髓系白血病(AML)安全有效, 不良反应可耐受, 可作为老年AML患者初始诱导化疗方案选择之一。
作者 牛建花 杨华 王晖 靖彧 Niu Jianhua;Yang Hua;Wang Hui;Jing Yu(Department of Hematology,the Forth People's Hospital of Jinan,Jinan 250031,China;Department of Hematology,The University of Hong Kong-Shenzhen Hospital,Shenzhen 518000,China;Department of Rheumatology,the Forth People's Hospital of Jinan,Jinan 250031,China;Department of Hematology,the Fifth Medical Center of PLA General Hospital,Beijing 100853,China)
出处 《白血病.淋巴瘤》 CAS 2024年第6期362-364,共3页 Journal of Leukemia & Lymphoma
基金 济南市卫生健康委员会科技发展计划(2022-2-79)。
  • 相关文献

参考文献2

二级参考文献18

  • 1Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011:29 ( 15 ) _. 1987 - 1996.
  • 2张之南,沈悌.血液学诊断及疗效标准.第3版,北京,科学出版社,2006.279-281.
  • 3Saba HI. Decitabine in the treatment of myelodysplastic syn- dromes. Ther Clin Risk Manag, 2007 ;3 (5) : 807 -817.
  • 4Qin T, Castoro R, E1 AS, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One, 2011 ; 6 (8) : 23372 -23382.
  • 5Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treaanent (ADOPT) trial. J Clin Oncol, 2009 ; 27 ( 23 ) : 3842 - 3848.
  • 6Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma,2008 ;49(4) : 690 - 695.
  • 7Santos FP, Kantarjian H, Garcia-Manero G, et al. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther, 2010;10(1) : 9 -22.
  • 8Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res, 2011 ; 35 (4) : 499 - 503.
  • 9Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood, 2011;117 (3) : 936 -941.
  • 10韦菊英,董晓燕,钱文斌,孟海涛,麦文渊,佟红艳,童茵,毛莉萍,金洁.83例老年急性髓系白血病临床分析[J].中华血液学杂志,2008,29(6):410-411. 被引量:6

共引文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部